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Crystal Engineering of Binary Compounds
Containing Pharmaceutical Molecules
Leslie Ann Morales
ABSTRACT

The synthesis or the interaction between two or more molecules is known as
supramolecular chemistry. The concept of supramolecular chemistry can be applied to
the design of new pharmaceutical materials affording new compositions of matter with
desirable composition, structure and properties.
The design of a two-molecule, or binary, compound using complementary
molecules represents an example of an application of crystal engineering. Crystal
engineering is the understanding of intermolecular interactions, in the context of crystal
packing, in the design of new solid materials. By identifying reliable connectors through
molecular recognition or self-assembly, one can build predictable architectures.
The study of supramolecular synthesis was accomplished using known
pharmaceutical molecules such as Nifedipine (calcium channel blocker used for
cardiovascular diseases) and Phenytoin (used as an anticonvulsant drug) and model
compounds containing synthons common in pharmaceutical drugs (Crown ethers and

viii

Trimesic acid with ether linkages and carboxylic acid dimers, respectively) with
complementary molecular additives.
The co-crystals formed were characterized by various techniques (IR, m.p., XPD,
single X-ray diffraction) and preliminary results were found to exhibit characteristics
different from the parent compounds as a direct result of hydrogen bonding and selfassembly interactions. These crystalline assemblies could afford improved solubility,
dissolution rate, stability and bioavailability.

ix

Chapter 1
Introduction
1.1 Supramolecular Chemistry and Crystal Engineering
The concept of crystal engineering was introduced by Pepinsky in 19551 and was first
applied by Schmidt in the context of covalent bond formation in the solid state, i.e.
topochemical reactions.2 More recent developments have expanded this concept into
areas as diverse as supramolecular synthesis, crystal structure analysis and prediction.3,4
Crystal engineering is a field that offers varying paths for the rational design of functional
solids.
Supramolecular synthesis offers a paradigm for the facile design and isolation of
supramolecular complexes using self-assembly of different, but complementary
supramolecular synthons. The subsequent ability to generate a diverse range of multiple
component crystalline solids affords new compositions of matter and an ability to engage
in systematic analysis of the factors that control structure/function relationships in the
solid state.
Self-assembly of pre-selected molecular components,5 or supramolecular synthesis,4,6
represents a paradigm for the generation of chemical structures with nanoscale features.
Supramolecular synthetic approaches offer a number of attractive features: the ability to
exploit readily available molecules or ions in novel ways, their inherent modularity
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affords compositional and structural diversity, and the use of non-covalent interactions
(such as ion-ion, ion-dipole, dipole-dipole, π-π stacking, Van der Waals forces and
hydrogen bonding) makes for facile synthesis. Supramolecular synthesis offers a
combinatorial type of approach to synthesis of new structures and can afford a wide range
of structural diversity without the need to break and form covalent bonds. The paradigm
is exemplified by the use of geometric considerations to guide the preparation of
nanoscale hydrogen bonded polyhedra7 and by development of rational approaches to the
design of ternary structures.The fact that hydrogen bonds are formed in a hierarchical
fashion (strongest H-bond acceptor to strongest H-bond donor, and so on) and that crystal
stability depends on specific intermolecular interactions8 is the basis for this arrangement.

(a)

(b)

(c)

Figure 1. Schematic representation of (a) supramolecular homosynthon (i.e. carboxylic acid dimer), (b)
supramolecular heterosynthon (i.e. a carboxylic acid- pyridyl dimer), (c) supramolecular heterosynthon (i.e.
ether linkage-amine).

1.2 Supramolecular Synthons
Supramolecular synthons6 depict the possible ways in which complementary
functionalities of molecules interact by non-covalent interactions. One of such
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interactions is the hydrogen bond. A hydrogen bond is a strong, directional, selective and
stabilizing interaction between a hydrogen atom and an electronegative atom. As
revealed by Figure 1, supramolecular synthons can either be self-complementary (a
supramolecular homosynthon such as a carboxylic acid dimer9) or the result of
complementary interactions between different moieties (a supramolecular heterosynthon
such as a DNA base pair or the well-known carboxylic acid-pyridyl interaction10). The
latter brings with it the opportunity to build multiple component superstructures and is
the main focus of this study.

1.3 Polymorphism
The occurrence of polymorphism in crystal engineering cannot be ignored.
Polymorphism is defined as the phenomenon where the same chemical substance exists
in different crystalline forms or different crystalline patterns.11 This trend is more
common among molecules with flexible conformations capable of hydrogen bonding.6
The internal arrangement of molecules in the solid state has a pronounced influence on
chemical and physical properties. In this context, the existence of more than one
crystalline form of a given compound, typically in the form of polymorphs or solvates,
represents both a problem and an opportunity12 in organic synthesis and early stage
development of pharmaceuticals.
Supramolecular synthons are the structural units within molecules, which can be
formed and/or assembled by synthetic operations6. The supramolecular synthons present
in polymorphic forms may be intact from form to form, therefore it can be stated that the
supramolecular equivalents of structural isomers are crystalline polymorphs6. The criteria
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for assessing the existence of polymorphs are different unit cell parameters, crystal
packing arrangements and physical properties.11
The study of the phenomenon of polymorphism has many implications. It has
increased due to the “great importance of legal and regulatory issues” that faces the
pharmaceutical industry to date.13 The US Patent Office permits a new phase (i.e.
polymorph, solvate or binary compound) of a drug to be patented if there is any
processing or bioavailability benefit to the new solid phase. This may be problematic
since many drug molecules are prone to polymorphism and crystal size and morphology
can vary for any given phase. This can have significant commercial relevance because
patents can be extended or effectively voided, translating into monetary gain or loss.

1.4 Cambridge Structural Database
As previously stated, crystal engineering and supramolecular chemistry are
intricately intertwined and the common theme between the two is the connection between
structure and architecture control via intermolecular interactions, namely hydrogen
bonding between supramolecular synthons. Self-assembly of the targeted synthons
through hydrogen bonding of complementary functional groups contributes to the control
and possible prediction of the supramolecular structure, thus changing the physical
properties of the material. Rationalization and design of these supramolecular solids is
the basis of crystal engineering. A survey of existing supramolecular synthons and
structures can be carried out through the Cambridge Structural Database (CSD).14 By
analyzing the existing structures and/or synthons in the CSD, new compositions of matter
can be obtained, achieving new phases with new properties. An extensive analysis of the
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supramolecular synthons involved in the compounds described in this thesis was carried
out and a library with average hydrogen bond distances was formulated. The CSD has a
total of 296,427 hits as of July 2003. Out of the 296,427 hits, 127,003 hits are considered
organic, and out of that subset, 118,322 are organics with no metals, which accounts for
~40% of the total hits in the CSD.14 All searches had as search parameters R factor
<0.075, no ions and organics only. All searches were done with specific hydrogen bond
distances, which were narrowed down through statistics and histograms. The distances
ranged from the two non-hydrogen atoms “sharing” the hydrogen atom since the
hydrogen atom cannot be given a specific position due to its movement.

1.4.1

Nifedipine Synthons

HN

N

N

O

O

HN

O

O

1

HN

2

3

O

HN

4

Figure 2. Supramolecular synthons in nifedipine

Table 1 Nifedipine Hydrogen bonded synthons and distances.

1
2
3
4

# hits
147
55
244
118

distance
2.8-3.25
2.8-3.4
2.8-3.3
2.8-3.1

min
2.801
2.847
2.806
2.801

Max
3.247
3.391
3.298
3.097

ave
3.074
3.148
3.006
2.917

std
0.1186
0.1313
0.1172
0.0752

Single* Multi*
122
25
48
7
224
20
106
15

*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on
the same molecules (single) or the formation between two molecules (multi) with complementary
synthons.
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Nifedipine has three possible hydrogen-bonding sites, the secondary amine (H-bond
donor), the ester carbonyl (H-bond acceptor) and the nitro group (H-bond acceptor). Out
of these three possible sites, the secondary amine is involved in hydrogen bonding most
often and there are many more structures or hits of this interaction in the CSD as can be
seen above. A secondary amide is involved in all of the CSD searches that were carried
out in the nifedipine analysis. The ester carbonyl and the nitro group form secondary
hydrogen bonds. nifedipine will always be involved in a heterosupramolecular synthon.
The use of the secondary amine as a designing tool seems promising since interactions
with this functional group is very prevalent in the CSD.

1.4.2

Phenytoin Synthons

O
N

H

H

N

X

O

O

HN

X

O
1

HN

2

X
X

N

3

HN
4

Figure 3. Supramolecular synthons in phenytoin

Table 2. Phenytoin Hydrogen bonded synthons and distances.

1
2
3
4

# hits
970
340
1441
147

Distance
2.4-3.3
2.7-3.2
2.7-3.2
2.8-3.25

min
2.707
2.701
2.7
2.801

max
3.297
3.2
3.198
3.247

mean
2.908
2.939
2.924
3.074

σ
0.1015
0.1195
0.1014
0.1186

Single* Multi*
804
166
283
57
1224
217
122
25

*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on
the same molecules (single) or the formation between two molecules (multi) with complementary synthons.
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Phenytoin has two hydrogen bond donors (secondary amine) and acceptors
(carbonyls) and they are complementary with one another as seen from the CSD searches.
Search number 2 is a subset of search 3 and makes the results more relevant toward
phenytoin. Phenytoin can hydrogen bond as amide dimers or as heterosynthons between
complementary functional groups or synthons present on different molecules. As seen in
the table above, the amide dimer is prevalent in structures containing the same molecule
and the average distance is very similar when considering other ways of forming
synthons.
1.4.3

Crown Ethers Synthons

H N

O

H N

O
X

H

1

N

2

3

18C6

H N

O

H N

O

+

H N

O

X

4

5

Figure 4. Supramolecular synthons in crown ethers

Table 3. Possible ether hydrogen bonded synthons and distances.

1
2
3
4
5

# hits
473
225
36
446
21

distance
2.8-3.35
2.8-3.35
2.8-3.35
2.8-3.35
2.8-3.35

min
2.801
2.801
2.801
2.801
2.801

max
3.349
3.348
3.345
3.349
3.314

ave
3.112
3.103
3.084
3.114
3.062

std
0.1319
0.1256
0.1226
0.1323
0.1246

Single* Multi*
328
141
133
92
26
10
319
127
21
0

*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on
the same molecules (single) or the formation between two molecules (multi) with complementary
synthons.
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Crowns ethers are deficient in hydrogen bond donors; therefore they are very
susceptible to forming hydrogen bonds when molecules with amines or any other
complementary hydrogen bonding functional group are present. Searches 2, 3 and 4 are
all subsets of search 1. Search 1 encompasses all possibilities, from primary amines,
secondary amides, pyridines, etc. Most of the structures or hydrogen-bonded synthons
found in the CSD regarding ethers involved the same molecule. On the contrary, when
18-crown-6 (18C6) was specified as the ether to be analyzed, none of the 21 hits involved
single molecules since 18C6 only has hydrogen bond donors. In this case, molecules
with complementary functional groups for hydrogen bonding were needed. This is an
example of how new phases and compositions of matter can be manipulated or designed
in order to achieve different physical properties.

1.4.4

Trimesic acid Synthons
O

HO

OH

O

1
Figure 5. Supramolecular synthons in trimesic acid
Table 4. Trimesic acid carboxylic acid dimer hydrogen bond distances

# hits
1193

distance
2.4-3.2

min
2.554

max
3.196

ave
2.657

std
0.0644

Single* Multi*
1059
134

1
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on
the same molecules (single) or the formation between two molecules (multi) with complementary
synthons.

Trimesic acid forms honeycomb networks by means of carboxylic acid dimers. The
carboxylic acid dimer is the basis for all of the TMA structures that will be discussed in
8

Chapter 5. There are many forms of TMA and all involve the carboxylic acid dimer.
The new structures incorporate a neutral guest in the cavities formed by six trimesic acid
molecules bonding in a honeycomb fashion (~14Å pore diameter). The distances of the
hydrogen bonds between the carboxylic acid functional groups on separate molecules are
very consistent when it comes to the network.

1.4.5 Secondary Hydrogen Bonds

H
X

H

X

N

H

O

X

H
1

2

Figure 6. Secondary hydrogen bonds involving methyl hydrogens and hydrogen bond acceptors nitrogen
and oxygen.

There are two secondary hydrogen bonds which need to be specified since they are
used to further stabilize the crystal packing of the supramolecular structures discussed in
this work. Synthon 1 is seen in the nifedipine/4,4’-dipyridyl structure while synthon 2 is
seen in the phenytoin/trans-1,2-(4-pyridyl) ethylene structure. Further discussion on all
of these structures will be available in the following chapters.

Table 5. Possible secondary hydrogen bond synthons and distances

1
2

# hits distance
10317 3.3-4.2
13921 3.35-4.2

min
3.4
3.349

max
3.199
4.199

ave
3.8872
3.8976

std
0.1038
0.1995

Single* Multi*
8606
1711
11766
2155

*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on
the same molecules (single) or the formation between two molecules (multi) with complementary
synthons.
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This thesis is based on the principles of crystal engineering in order to generate
new compositions of matter through supramolecular synthesis and self-assembly of
complementary synthons. This presents an increase in the potential need to control solidstate structures, changing their physical properties and leading to improved solubility and
bioavailability. The study chose pharmaceutical molecules as the target system since
they contain a wide range of synthons and understanding of the crystal structure –
physical property relationship is essential for the continued application of these essential
chemicals toward improving the overall health of society.
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Chapter 2
Nifedipine
2.1 Description

NO2
H3COOC

H3C

COOCH3

N

CH3

H

Figure 7. Pure nifedipine stick models. Oxygen atoms are in red (hydrogen bond acceptor); nitrogen atoms
are in blue (hydrogen bond donor). All hydrogen atoms on the figure to the right have been omitted for
clarity.

Nifedipine,15 with MW of 246.34g/mol and m.p. of 172-174°C, is a calcium
antagonist used in the treatment of cardiovascular disorders such as hypertension and
angina pectoris. Nifedipine exhibits low water solubility (less than 10µg/mL) and erratic
bioavailability. There is a direct correlation between structure and function of new
pharmaceutical phases of nifedipine. Modifying the structure of the compound, thus
creating new and different phases, may affect different properties. Differing the phases
or crystalline self-assemblies of nifedipine may improve the drug's solubility, dissolution
rate, stability and bioavailability.
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Dihydropyridine chemistry16 began in 1882 when Hantzsch first reported
dihydropyridines as stable intermediates in the pyridine synthesis that bears his name.
The recent interest in dihydropyridines can be traced to the coenzyme reduced
nicotinamide adenine dinucleotide (NADH) and the unique ability of this compound in
biological systems to reduce unsaturated functional groups.15 In 1949 A.P. Phillips
reported on the weak analgesic and curare-like activities of a few dihydropyridine
derivatives. In the search for orally active drugs for the treatment of coronary
insufficiency, F. Bosset synthesized in 1966 a compound designated Bay a 1040, which
following its introduction as nifedipine in 1975 has since become one of the major
cardiovascular drugs.
Nifedipine16 is sensitive to light in solid form and extremely sensitive to light in
dissolved state in solution. In the crystal lattice, the almost flat dihydropyridine ring lies
at a practically perpendicular angle to the nitrophenyl group, the ortho-nitro group facing
away from the dihydropyridine ring. Under the influence of visible and ultra-violet light
nifedipine in solutions is converted into a nitroso compound.

2.2 Strategy
In view of the fact that nifedipine contains hydrogen bond acceptors and donors,
complementary molecules can be compounds with both acceptor and donor synthons.
The main hydrogen-bonding site is the secondary amine, which can bond to carbonyl as
well as nitrogen (e.g. pyridines).
Crystals of A, B and C were obtained via slow evaporation of stoichiometric amounts
of nifedipine and cocrystal formers in the appropriate solvents. All crystallization
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experiments were conducted in an unmodified atmosphere and the solvents were dried by
standard methods prior to use. All chemicals used are commercially available and were
purchased from Aldrich®.

Table 6. Nifedipine Supramolecular Complexes

Nifedipine/formamide
Nifedipine/isonicotinamide
Nifedipine/4,4'-dipyridyl

A
B
C

N
O
H

NH2

NH2

N

N

O
FORMAMIDE

ISONICOTINAMIDE

4,4'-DIPYRIDYL

Figure 8. Structures of the co-crystal formers used in the supramolecular complexes involving nifedipine.

2.3 Structures
2.3.1 Nifedipine/formamide (A)
Crystallization of nifedipine from formamide results in a 1:1 supramolecular
complex that is sustained by amine-carbonyl H-bonds. In A, as revealed by Figure 3
(synthons 3), one of the hydrogen atoms in the amino moiety of the formamide hydrogen
bonds to the carbonyl oxygen of the ester on one nifedipine molecule with bond distance
of 3.024Å, which falls well within the distance range found in the CSD and stated in
chapter 1 (nifedipine search 3) of 2.8-3.3 Å. The other amine hydrogen atom found in
formamide is engaged in a hydrogen bond with the nitro oxygen on another nifedipine
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molecule. The distance for this bond is 3.155 Å and falls within the range obtained from
the CSD search (nifedipine search 2) for this synthon (2.8-3.4 Å). Formamide has two
hydrogen bond donors (the amine hydrogens) but also has a hydrogen bond acceptor (the
aldehyde carbonyl). The carbonyl is also involved in a hydrogen bond with a third
nifedipine molecule. The carbonyl is bonded to the secondary amine of the nifedipine
molecule and has a distance of 2.906 Å and falls within the range set from the CSD
search (nifedipine search 4) of 2.8-3.1 Å.

Figure 9. The 1:1 adduct formed between nifedipine and formamide. The hydrogen-bonded motif is also
shown.

2.3.2 Nifedipine/isonicotinamide (B)
Crystallization of nifedipine and isonicotinamide from methanol results in a 1:1
supramolecular complex that is sustained by amine-carbonyl and amine-pyridine Hbonds. In B, as revealed by Figure 4, one of the hydrogen atoms in the amino moiety of
the Isonicotinamide hydrogen bonds to the carbonyl oxygen of the ester on one nifedipine
molecule with bond distance of 3.097Å which falls well within the distance range found
in the CSD and stated in chapter 1 (nifedipine search 3) of 2.8-3.3 Å. The other amine
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hydrogen atom found in isonicotinamide is engaged in a hydrogen bond with another
isonicotinamide molecule. The distance for the amine hydrogen and the pyridine
nitrogen bond on separate isonicotinamide molecules is 2.911 Å and falls within the
range obtained from the CSD search (nifedipine search 1) for this synthon (2.8-3.25 Å).
Isonicotinamide has two hydrogen bond donors (the amine hydrogens) but also has a
hydrogen bond acceptor (the amide carbonyl). This carbonyl oxygen is involved in a
hydrogen bond to a second nifedipine molecule. The carbonyl is bonded to the secondary
amine of the nifedipine molecule and has a distance of 2.878 Å and falls within the range
set from the CSD search (nifedipine search 4) of 2.8-3.1 Å. B differs from A in that a
new synthon is involved, the amine-pyridine hydrogen bond is seen in B which facilitates
many more arrangements and new phases for nifedipine.

Figure 10. The 1:1 adduct formed between nifedipine and isonicotinamide.

2.3.3

Nifedipine/4,4’-dipyridyl (C)

Crystallization of nifedipine and 4,4’-dipyridyl from methanol results in a 1:1
supramolecular complex which is sustained by amine-pyridine H-bonds. 4,4’-dipyridyl is
only a hydrogen bond acceptor; therefore the secondary amine in the nifedipine is the
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most likely hydrogen bonding site. In C, as revealed by Figure 5, the amine-pyridine
hydrogen bond is evident with a bond distance of 3.134Å. This distance does fall within
the nifedipine CSD search from chapter 1 (search 1, 2.8-3.25 Å). A secondary hydrogen
bond is formed between one methyl hydrogen (from the ester group) and the other
pyridine nitrogen available. This bond’s purpose is for stability in the crystal packing and
the distance is 3.295 Å. The range distance for this secondary hydrogen bond is 3.3-4.2
Å; therefore, it is on the lower limit of this type of bond (Search 1, section 1.25).

Figure 11. The 1:1 adduct formed between nifedipine and 4,4’-dipyridyl.

2.4
2.4.1

Synthesis and Results
Nifedipine/formamide (A)

Synthesis: In a typical reaction, 32 mg (1.29x10-4 mol) of nifedipine was dissolved in 2
mL of formamide. The reaction vial was kept tightly capped to avoid any solvent
evaporation. The vial was covered in aluminum foil to protect from light. In
approximately two days yellow crystals appeared.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix A
Crystal packing: Crystallization of nifedipine from formamide results in a 1:1
supramolecular complex that is sustained by amine-carbonyl H-bonds. Distances range
between 3.024-3.155Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3443, 3303 cm-1 (N-H stretch, 1°
amine, formamide); 1684 cm-1 (C=O stretch, formamide) 1310, 1248, 1217 cm-1 (C-O
stretching).
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Melt-temp: 136-138°C
X-ray powder diffraction: in 2θ, simulated derived from the single crystal data;
experimental (simulated): 8.461(8.850), 9.955(9.923), 12.682(12.893), 13.080(13.420),
14.954(15.307), 16.966(17.022), 17.082 (17.034), 21.036(20.827), 23.539(23.437),
24.658(24.682), 26.725(26.715), 27.039(27.028).
2.4.2

Nifedipine/isonicotinamide (B)

Synthesis: In a typical reaction, 31 mg (1.26x10-4 mol) of nifedipine and 28 mg
(2.29x10-4 mol) of isonicotinamide were dissolved in approximately 1 mL of methanol.
Slow evaporation of the solvent for approximately a week yielded 1:1 crystals. The
reaction vial was covered in aluminum foil to prevent light degradation.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix A
Crystal packing: Crystallization of nifedipine and isonicotinamide from methanol results
in a 1:1 supramolecular complex that is sustained by amine-carbonyl and amine-pyridine
H-bonds. Distances range between 2.878-3.097Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3408 cm-1 (N-H stretch, 2° amine);
3286 cm-1 (-OH stretch); 1669 cm-1 (C=O stretch); 1209, 1118 cm-1 (C-O stretching).
Melt-temp: 148-153°C
X-ray powder diffraction: in 2θ, simulated derived from the single crystal data;
experimental
(simulated):
10.418(10.636),
11.561(11.823),
11.880(11.849),
13.003(13.212), 19.404(19.739), 19.660(19.771), 21.142(21.167), 22.739(22.779),
23.739(23.774), 26.399(26.407), 31.820(31.806).
2.4.3

Nifedipine/4,4’-dipyridyl (C)

Synthesis: In a typical reaction, 30 mg (1.22x10-4 mol) of nifedipine and 43 mg
(2.75x10-4 mol) of 4,4’-dipyridyl were dissolved in approximately 1 mL of methanol.
Slow evaporation of the solvent for approximately two week yielded 1:1 nifedipine/4,4’dipyridyl crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix A
Crystal packing: Crystallization of nifedipine and 4,4’-dipyridyl from methanol results in
a 1:1 supramolecular complex that is sustained by amine-pyridine H-bonds. 4,4’Dipyridyl is only a hydrogen bond acceptor; therefore the secondary amine in the
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nifedipine is the most likely hydrogen bonding site. Distances range between 3.1343.295Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3275 cm-1 (N-H stretch, 2° amine);
3213 (-OH stretch); 1687 cm-1 (C=O stretch); 1263, 1208 cm-1 (C-O stretching).
Melt-temp: 137-139°C
X-ray powder diffraction: experimental done, calculated could not be done. 4.039,
11.459, 12.281, 19.362, 20.200, 21.601, 24.802, 24.958, 25.340, 25.419.
2.5 Discussion
Presented above were three examples of the use of supramolecular synthesis to
generate new compositions of matter containing molecules of interest to materials
scientists. These supramolecular complexes show how secondary amines, nitro groups
and carbonyls present in pharmaceutical drugs can be exploited via crystal engineering.
This has increased the potential to control solid-state structures, changing their physical
properties and leading to improved solubility and bioavailability. Pure nifedipine Hbonds forming a chain, secondary amine to ether carbonyl, but as seen in the previous cocrystals, other synthons are exploited and the crystal structure therefore has to adjust.
Careful analysis of the existing supramolecular synthons on nifedipine provides an
educated guess that allows scientists to choose other molecules with complementary
components, designing supramolecules. The exact connection sites for the synthons
cannot always be predicted since other factors such as solvent, sterics and number of
possible hydrogen bonding sites has a powerful effect on the outcome.
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Chapter 3
Phenytoin
3.1. Description

H

O
N

H

N

O

Figure 12. Pure phenytoin stick models. Oxygen atoms (in red) are the hydrogen bond acceptors and the
nitrogen atoms (in blue) are the hydrogen bond donors. Hydrogen atoms have been deleted for clarity.

Phenytoin,17 or 5,5-diphenylhydantoin, is a pharmaceutical drug used for the
treatment of seizures. It is sparingly soluble in water (20-25mcg/mL). Compounds with
aliphatic side groups at position C5 are commonly used as sedatives, and phenyl rings at
this position lead to anticonvulsant properties without the need to impair consciousness.
It is also sparingly soluble in ethanol and acetone and has a M.W. of 252.272g/mol and
m.p. of 295°C. According to Chakrabati,18 phenytoin exists in two forms. Form 1:
rodlike plates or regular crystalline shape, and form 2: needle shaped. The existence of
these two forms is due to differences in the crystalline state.
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In 1938 Merrit and Putnam19 found that 5,5-diphenylhydantoin (phenytoin) showed
anticonvulsant properties. Twelve years later it was stated that apart from antiepileptic
activity, phenytoin possessed antiarrhythmic activity. It belongs to class 1b according to
Vaughan Williams classification of antiarrhythmic agents modulating voltage-gated
sodium channels conductance. Limited clinical effectiveness and undesired side effects
are the driving force to using supramolecular chemistry in order to change the structure,
therefore changing the physical properties since there is a direct correlation between the
two.
Diphenylhydantoin and phenobarbital are the most widely used drugs in the treatment
of grand mal, psychomotor, and focal epilepsies. The similarity of barbiturates to uracil
has prompted investigations into their hydrogen-bonding capabilities with adenine
molecules. Some of the biological effects of these drugs may derive from an ability to
specifically bind and inactivate adenine-containing nucleic acids or coenzymes.20
Comparisons of the complexes formed by these drugs with adenine containing molecules
may prove helpful in understanding the modes of action of these drugs.20

Figure 13. Hydrogen bonded motif of pure phenytoin.

The crystals are orthorhombic and systematic absences indicate space groups Pnma or
Pn21a. Pn21a (centrosymmetric space group), indicated by structure analysis, was yielded
by the hydantoin group atomic positions even though the true space group for phenytoin
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is non-centrosymmetric, but the proximity of the hydantoin group plane was very close to
0 or π (approximating a centrosymmetric arrangement in the unit cell). The hydrogenbonded motif, figure 2, shows the hydrogen bonds between amine hydrogens and
carbonyl oxygens between phenytoin molecules with distances ranging from 2.784-2.844
Å. These distances fall within the range obtained from the CSD search in Chapter 1
(phenytoin search 2) which is 2.7-3.2 Å.

3.2 Strategy
In view of the fact that phenytoin has both hydrogen bond acceptors (carbonyl
oxygens) as well as hydrogen bond donors (secondary amines), a complementary
molecule can be one that has at least one hydrogen bond acceptor moiety (example
amines, alcohols, carboxylic acids, etc.) or at least one hydrogen bond donor moiety
(amines, amides, alcohols, etc). Phenytoin has the added characteristic that it can form
amide dimers between two phenytoin molecules since the synthon is complementary with
itself.
Crystals of A, B, and C were obtained via slow evaporation of stoichiometric amounts
of phenytoin and cocrystal formers in the appropriate solvents. All crystallization
experiments were conducted in an unmodified atmosphere and the solvents were dried by
standard methods prior to use. All chemicals used are commercially available and were
purchased from Aldrich®.
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Table 7. Phenytoin Supramolecular Complexes

Phenytoin/4(1H) pyridone
Phenytoin/4,4'-dipyridyl
Phenytoin/trans-1,2-bis(4-pyridyl) ethylene

A
B
C

O
H

H
N

H

N

N

N

N

H

H

4(1H)-PYRIDONE

4,4'-DIPYRIDYL

TRANS-1,2-BIS(4-PYRIDYL)ETHYLENE

Figure 14. Structures of the co-crystal formers used in the supramolecular complexes involving phenytoin.

3.3 Structures
3.3.1 Phenytoin/4(1H)-pyridone (A)
Crystallization of phenytoin and 4-hydroxypyridine (which later tautomerized to
4(1H)-pyridone) from ethanol results in a 1:1 supramolecular complex that is sustained
by amine-carbonyl H-bonds between phenytoin molecules and pyridone molecules. In A,
as revealed by Figure 4, there is a chain formed of phenytoin molecules. The pyridones
also arrange consecutively with one another forming another chain by means of NH…O=C bonds. These hydrogen bonds average 2.665 Å, well within the range obtained
from the CSD (2.7-3.2 Å). These two independent chains, phenytoin and pyridone, are
connected to each other by means of another N-H…O=C bond. The carbonyl present in
the pyridone molecule is bifurcated, H-bonding to both the secondary amine in phenytoin
as well as the secondary amine in the pyridone molecule. In the crystal packing of A one
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can observe that two pyridone chains are sandwiched between two phenytoin chains. If
one examines figure 2 one can see how that motif was simply expanded enough to fit the
two H-bonded pyridone chains.

Figure 15. The 1:1 adduct formed between phenytoin and 4(1H) pyridone. The hydrogen bonded crystal
packing is shown to the left.

3.3.2

Phenytoin/4,4’-dipyridyl (B)

Crystallization of phenytoin and 4,4’-dipyridyl from 2,4-pentanedione results in a 1:1
supramolecular complex that is sustained by amine-pyridine H-bonds between the
phenytoin and 4,4’-dipyridyl (Bipy) molecules as well as phenytoin amide dimers. In B,
(Figure 5) there is a chain of phenytoin and bipy molecules formed. The N-H…N
distance is 2.861Å and falls within the distance range obtained from the CSD search in
Chapter 1 (phenytoin search 4), which is 2.8-3.25 Å. The phenytoin molecules also Hbond and form amide dimers. The hydrogen bond distance between the N-H….O=C
dimers on separate phenytoin molecules is 2.791 Å and according to the information
obtained from the CSD searches on Chapter 1 (phenytoin search 1) fall within the
distance range of 2.4-3.3Å. The phenytoin molecules arrange in dimers and the
secondary amine not involved in the dimer is available to H-bond to the pyridine nitrogen
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of the 4,4’-dipyridyl, forming a zigzag chain. The other carbonyl is not involved in any
other hydrogen bonds. The crystal packing of this supramolecular structure orients the
hydrophobic phenyl rings on the inside of the chains, keeping the hydrophilic parts of the
structure on the outside and susceptible to forming bonds with complementary synthons
(figure 5).

Figure 16. The 1:1 adduct formed between phenytoin and 4,4’-dipyridyl. The hydrogen bonded crystal
packing is shown.

3.3.3

Phenytoin/trans-1,2-bis(4-pyridyl) ethylene (C)

Crystallization of phenytoin and trans-1,2-bis(4-pyridyl) ethylene from 2,4pentanedione results in a 1:5 supramolecular complex that is sustained by amine-pyridine
H-bonds between the phenytoin and trans-1,2-bis(4-pyridyl) ethylene molecules as well
as dimers between the phenytoin amides. In C (Figure 6), there is a chain formed of
phenytoin and trans-1,2-bis(4-pyridyl) ethylene molecules. The N-H…N distance is 2.844
Å and falls within the distance range obtained from the CSD search on Chapter 1
(phenytoin search 4) which is 2.8-3.25 Å. The phenytoin molecules also H-bond and
form amide dimers. The hydrogen bond distance between the N-H….O=C on separate
phenytoin molecules is 2.891 Å and according to the information obtained from the CSD
searches on Chapter 1 (phenytoin search 1) falls within the distance range of 2.4-3.3Å.
Structure C is very similar to structure B in its hydrogen bonding, the only difference is
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that in addition to forming dimers between the phenytoin molecules and N-H…N bond to
the additive, there are also additives interacting in a secondary hydrogen bond with the
available phenytoin carbonyl. The bond distance is 3.386 Å and falls within the range for
the CH…O carbonyl synthon (range 3.1-3.9 Å). This hydrogen bond permits the trans1,2-bis(4-pyridyl) ethylene to stay in the cavity.
The phenytoin molecules arrange in dimers and the secondary amine not involved in
the dimer is available to H-bond to the pyridine nitrogen of the trans-1,2-bis(4-pyridyl)
ethylene, forming a zigzag chain. The crystal packing of this supramolecular structure
arranges in such a way that allows for the accommodation of an additive molecule in the
hydrophobic cavity.

Figure 17. The 1:5 adduct formed between phenytoin and trans-1,2-bis(4-pyridyl) ethylene. The hydrogen
bonded crystal packing is shown.

3.4 Synthesis and Results
3.4.1

Phenytoin/4(1H)-pyridone (A)

Synthesis: In a typical reaction, 28 mg (1.11x10-4 mol) of phenytoin and 11 mg
(1.16x10-4 mol) of 4-hydorxypyridine (which later tautomerizes to 4(1H)pyridone) were
dissolved in approximately 2 mL ethanol and 1 mL acetone. The reaction vial was kept
tightly capped to avoid solvent evaporation. After a few weeks clear 1:1 crystals formed.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix B
Crystal packing: Crystallization of phenytoin and 4-hydroxypyridine (which later
tautomerized to 4(1H)-pyridone) from ethanol results in a 1:1 supramolecular complex
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that is sustained by amine-carbonyl H-bonds between phenytoin molecules and pyridone
molecules. Distances averaged 2.665Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3311 cm-1 (N-H stretch, 2° amine,
phenytoin); 1758, 1711, 1497cm-1 (C-O stretching).
Melt-temp: 234-239°C
X-ray powder diffraction: in 2θ, simulated derived from the single crystal data;
experimental (simulated): 5.336(5.212), 11.332(11.137), 15.250(15.097), 16.419(16.228),
17.000(17.763), 17.977(18.019), 19.364(19.362), 19.679(19.821), 20.055(20.341),
21.417(21.160), 23.724(23.341), 26.348(26.054), 26.628(26.418), 27.643(27.260),
29.868(29.479).
3.4.2

Phenytoin/4,4’-dipyridyl (B)

Synthesis: In a typical reaction, 28 mg (1.11x10-4 mol) of phenytoin and 19 mg
(1.22x10-4 mol) of 4,4’-dipyridyl were dissolved in approximately 1 mL of 2,4pentanedione. Slow evaporation of the solvent for a few weeks yielded 1:1 crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix B
Crystal packing: Crystallization of phenytoin and 4,4’-dipyridyl from 2,4-pentanedione
results in a 1:1 supramolecular complex that is sustained by amine-pyridine H-bonds
between the phenytoin and 4,4’-dipyridyl (bipy) molecules as well as phenytoin amide
dimers. Distances range between 2.791-2.861Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). N/A
Melt-temp: 225-227°C
X-ray powder diffraction: experimental done, calculated could not be done. 12.974,
17.461, 18.798, 20.613, 22.180, 24.902, 26.717, 28.599, 31.931.

3.4.3

Phenytoin/trans-1,2-bis(4-pyridyl) ethylene (C)

Synthesis: In a typical reaction, 29 mg (1.15x10-4 mol) of phenytoin and 108.35 mg
(5.93x10-4 mol) of trans-1,2-bis(4-pyridyl) ethane were dissolved in approximately 1 mL
2,4-pentanedione. Slow evaporation of the solvent for approximately a week yielded
yellow 1:5 crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix B
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Crystal packing: Crystallization of phenytoin and trans-1,2-bis(4-pyridyl) ethane from
2,4-pentanedione results in a 1:5 supramolecular complex that is sustained by aminepyridine H-bonds between the phenytoin and trans-1,2-bis(4-pyridyl) ethane molecules as
well as dimers between the phenytoin. Distances range between 2.844-3.273Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3264, 3194 cm-1 (N-H stretch, 1°
amine); 3066, 3029 cm-1 alkenes; 1713 cm-1 (C=O stretch); 1310, 1248, 1209 cm-1 (C-O
stretching), 985 cm-1 (aromatic hydrogens).
Melt-temp: 254-257°C
X-ray powder diffraction: experimental done, calculated could not be done. 15.919,
19.370, 19.866, 2.159, 22.089, 22.215, 23.815, 34.826, 36.701.

3.5 Discussion
Presented above were three examples of the use of supramolecular synthesis to
generate new compositions of matter that contains molecules of interest to materials
scientists. These supramolecular complexes show how carbonyl and secondary amines if
viewed separately, or known as amides if both synthons (functional groups) are viewed
together, in pharmaceutical drugs can be exploited via crystal engineering. This has
increased the potential to control solid-state structures, changing their physical properties
and leading to improved solubility and bioavailability. Pure phenytoin makes full use of
all available synthons when hydrogen bonding, forming a tape. In the co-crystals,
modifications to this hydrogen bonded motif are necessary when accommodating other
complementary compounds. Not all available synthons will be exploited, as see in
structure A, where one of the two carbonyls available in each phenytoin molecule is not
involved in a hydrogen bond with another phenytoin molecule, additive molecule or
solvent molecule. In structure B, the supramolecular tape found in pure phenytoin has
been expanded to accommodate the bipy molecules. Phenytoin molecules still hydrogen
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bond to each other forming dimers. One secondary amine is involved in the hydrogen
bond with the bipy molecule, but the other carbonyl is not involved in a synthon (as seen
with structure A). Structure C is very similar to structure B, having the same hydrogen
bonding with the additive and also an available carbonyl not involved in a hydrogen
bond, but differs in that it fits another additive molecule in the cavities formed from the
arrangements of the Phenytoin/trans-1,2-(4-pyridyl) ethylene chains. This elucidates the
fact that just because the same synthons are being used, does not mean that the same
arrangements will be seen from structure to structure.
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Chapter 4
Crown Ethers
4.1 Description
Crown ethers are toxic compounds and serve as model compounds for
pharmaceutical molecules that contain ether linkages. Ether moieties are deficient in Hbond donors and contain excess H-bond acceptors. They are therefore predisposed to
become involved in supramolecular heterosynthons and it should not be surprising that
well known ethers such as 18-Crown-621 (18C6) and Dibenzo-18-Crown-622 (DB18C6)
form co-crystals and solvates with complementary molecules. Since the crown ether has
only hydrogen bond acceptors (oxygen atoms), a complementary molecule should be one
that has at least one hydrogen bond donor moiety (amines, alcohols, carboxylic acids,
etc.). The pure phase for 18C621 has been isolated, and the pure phase for DB18C6 has
been solved, but is pending publication.

O
O

O

O

O
O

Figure 18. Pure Dibenzo-18-crown-6 stick models. Oxygens (in red) are the hydrogen bond acceptors.
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Figure 19. Pure 18-crown-6 stick models. Oxygens (in red) are the hydrogen bond acceptors.

4.2 Polymorphism
The phenomenon of polymorphism in crystal engineering cannot be ignored.
Polymorphism is defined as the phenomenon where the same chemical substance exists
in different crystalline forms or different crystalline patterns.11 This phenomenon is more
common among molecules with flexible conformations capable of hydrogen bonding.6
Supramolecular synthons are the structural units within molecules, which can be formed
and/or assembled by synthetic operations.6 The supramolecular synthons present in
polymorphic forms may be intact from form to form, therefore it can be stated that the
supramolecular equivalents of structural isomers are crystalline polymorphs.6 The
criteria for assessing the existence of polymorphs are different unit cell parameters,
crystal packing arrangements and physical properties.6

4.3 Strategy
In view of the fact that the crown ethers only have hydrogen bond acceptors (oxygen
atoms), a complementary molecule should be one that has at least one hydrogen bond
acceptor moiety (example amines, alcohols, carboxylic acids, etc.). A survey of the
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Cambridge Structural Database (CSD) 14 shows that out of 362 hits (146 singlecomponent, 208 multi-component) for 18C6 foundation, 177 included metals, 39 had
hydrogen bonding to amine groups, and the remaining 88 hits were of crown derivatives.
The same trend was observed for DB18C6. Out of the 26 hits (15 single-component, 11
multi-component), 16 included metals, and only one hit had a hydrogen bond to an amine
group. The remaining three hits were DB18C6 derivatives. No hits showed hydrogen
bonding with amine groups and the remaining 13 hits were of crown derivatives.
Crystals of A, B, C, D, E, F, G, and H were obtained via slow evaporation of
stoichiometric amounts of crown ether and cocrystal formers in the appropriate solvents.
All crystallization experiments were conducted in an unmodified atmosphere and the
solvents were dried by standard methods prior to use. All chemicals used are
commercially available and were purchased from Aldrich®.

Table 8. Crown ether Supramolecular Complexes

Dibenzo-18-crown-6/4-nitroaniline
Dibenzo-18-crown-6/2-methyl-4-nitroaniline
Dibenzo-18-C-6/nicotinamide Polymorph A
Dibenzo-18-C-6/nicotinamide Polymorph B
18-crown-6/2,6-diaminopurine
18-crown-6/dicyandiamide
18-crown-6/5-aminoisophthalic acid
18-crown-6/tetrafluoroisophthalic acid/H2O
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Figure 20. Structures of the co-crystal formers used in the supramolecular complexes.

4.4 Structures
4.4.1 Dibenzo-18-crown-6/4-nitroaniline (A)
Crystallization of DB18C6 and 4-nitroaniline from benzene affords a 1:1 co-crystal, A.
Grinding a 1:1 mole ratio of DB18C6 and 4-nitroaniline also forms the co-crystal. As
revealed by Figure 4, the amine moiety forms H-bonds with four of the six ether oxygens
and generates a supramolecular complex. The hydrogen bond distances between the
oxygen atoms in the ether linkages closest to the aromatic rings and the bifurcated
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hydrogens in the amino group range from 3.050-3.145Å, with the 4-nitroaniline bonded
to the outside of the crown ether bowl.

Figure 21. The 1:1 adduct formed between DB-18-C-6 and 4-nitroaniline.

These supramolecular complexes pack into tubular arrangements with solvent
channels on the interior of the nanotubes (Figure 5). The tubular structure is not
sustained by π-π stacking or C-H…O- C hydrogen bonding. The tubular arrangements are
held together through steric effects.

Figure 22. Stick and space-filling models of one of the nanotubes formed by self-assembly of DB18C6/4nitroaniline. The nanotubes have an exterior diameter of ca. 2.3nm and the solvent channels have an
effective cross-section of 0.35nm.

The nature of the crystal packing is of particular note since the nanotubes are
inherently polar and they crystallize parallel to one another. Furthermore, as revealed by
Figure 6, the 4-nitroaniline molecules are oriented at ca. 60o to the polar axis. This
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represents a close to ideal alignment of dipoles that in most systems is usually frustrated
because of the tendency of molecules with high polarizability to pack in anti-parallel
arrangements.23
(a)

(b)

Figure 23. Views of the orientation of the p-nitroaniline molecules in 1: (a) parallel to the polar axis; (b)
looking down the polar axis.

4.4.2

Dibenzo-18-crown-6/2-methyl-4-nitroaniline (B)

Figure 24. The 1:1 adduct formed between DB-18-C-6 and 2-methyl-4-nitroaniline.

Crystallization of DB18C6 and 2-methyl-4-nitroaniline also results in a 1:1
supramolecular complex that is sustained by amine-ether H-bonds. In B, as revealed by
Figure 7, the amino moiety hydrogen bonds through the outside of the bowl to three
oxygen atoms of the crown. One amino hydrogen is bifurcated, the other is not. The
distances between the hydrogen atoms of the 2-methyl-4-nitroaniline and the oxygen
atoms of the ether linkages range from 2.695-3.465Å. However, in this case, non-
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centrosymmetric crystals are obtained. The molecule contains a donor amine and an
acceptor nitro group at the para position. This positioning allows for maximum
acentricity of the molecule. A methyl group is substituted at the ortho position, which
affects the non-centrosymmetric structure. The methyl group may also act as weak Hbond donor, but it is not evident in this case.24

4.4.3

Dibenzo-18-crown-6/nicotinamide Polymorph A (C)

Nicotinamide,25 vitamin B3 and a well known hydrotropic agent, was chosen as a
complementary additive to DB18C6 due to the presence of the amino group.
Crystallization of DB18C6 and nicotinamide from THF results in a 1:1 supramolecular
complex that is sustained by amine-ether H-bonds. Nevertheless, this supramolecular
organic solid is distinguished by the fact that it can form two crystalline phases that differ
in how the amine moieties H-bond to the DB18C6 molecules. In C, the amine group of
the nicotinamide molecule is hydrogen bonded to the ether oxygens through the outside
part of the crown bowl. The hydrogen bond distances between the hydrogen to the
oxygen range from 3.134 to 3.362Å

Figure 25. Outside bowl polymorphic form of the 1:1 adduct formed between DB18C6 and nicotinamide.
Crystal Packing of the 1:1 polymorphic co-crystals of DB18C6 and nicotinamide.
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4.4.4 Dibenzo-18-crown-6/nicotinamide Polymorph B (D)
In D the nicotinamide molecule is hydrogen bonded to the inside of the crown bowl
with hydrogen bond distances ranging from 2.995 to 3.043Å. A notable difference
between the hydrogen bonding of the two polymorphic forms is the fact that in C, one
hydrogen from the amino group bifurcates and bonds to two oxygen atoms closets to one
benzene ring.

Figure 26. Inside bowl polymorphic form of the 1:1 adduct formed between DB18C6 and nicotinamide
Crystal Packing of the 1:1 polymorphic co-crystals of DB18C6 and nicotinamide.

In D, each hydrogen atom from the amine is involved in a hydrogen bond with one
of the oxygen atoms, not being the same two oxygen atoms as in C. In the CSD,5 seven
structures have been reported of co-crystals involving crown ethers [DB18C6 (1
structure) and 18C6 (6 structures)] hydrogen bonded to amino groups.

4.4.5

18-crown-6/2,6-diaminopurine (E)

Crystallization of 18C6 and 2,6-diaminopurine from ethanol affords a 1:1 co-crystal, E.
As revealed by Figure 11, co-crystal E is sustained by hydrogen bonds between the
secondary amine hydrogen from the 2,6-diaminopurine molecule and an ether linkages
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from the crown. Two 2,6-diaminopurine molecules are involved in a dimer (NH2…N).
The secondary amine is then H-bonded to a crown oxygen. Distances range between
2.836-3.072Å.

Figure 27. The 1:1 adduct of 18C6 and 2,6-diaminopurine

4.4.6

18-crown-6/dicyandiamide (F)

Crystallization of 18C6 and dicyandiamide affords a 1:1 supramolecular complex. The
co-crystal, F, as shown in Figure 12, is sustained by hydrogen bonds from the two amino
group hydrogens from the dicyandiamide and two ether linkages from the crown.
Distances range between 2.901-2.998Å. Only one hydrogen atom from each amine
group is involved in a hydrogen bond with the ether linkages. The other hydrogen atoms
are hydrogen bonded to other dicyandiamides, as in the 2,6-diaminopurine dimers of cocrystal E. Crown ether sheets are interlinked to each other by means of the
dicyandiamide.
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Figure 28. The 1:1 adduct of 18C6 and dicyandiamide.

4.4.7

18-crown-6/5-aminoisophthalic acid (G)

Crystallization of 18C6 and 5-aminoisophthalic acid affords a 1:1 supramolecular
complex. The co-crystal, G, as shown in Figure 13, is sustained in a honeycomb network
by carboxylic acid dimers between the 5-aminoisophthalic acids and between amino
hydrogens from the 5-aminoisophthalic acid and the crown ether linkages. Distances
range between 2.545-2.748Å for the carboxylic acid dimer and 3.008-3.179 Å for the two
amino hydrogens and two ether linkages. Two zigzag 5-aminoisophthalic acid chains are
H-bonded to each other through the amino-ether H-bonds, forming the honeycomb
network. Each crown ether is bonded to two amine groups of the 5-aminoisophthalic
acid molecule, one above and one below.

Figure 29. The 1:1 adduct of 18C6 and 5-aminoisophthalic acid.
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4.4.8

18-crown-6/tetrafluoroisophthalic acid/H2O (H)

Crystallization of 18C6 and tetrafluoroisophthalic acid/H2O affords a 1:1
supramolecular complex. The co-crystal, H, as shown in Figure 14, is sustained by
hydrogen bonds through a bridging water molecule. The hydroxy group of the carboxylic
acid is H-bonded to the oxygen in the water molecule and the distances range from 2.8562.891Å. The water hydrogens are then H-bonded to two ether linkages at a distance of
2.553 Å. The tetrafluoroisophthalic acid bonded to the water molecule, which is then Hbonded to the crown ether forming a screw.

Figure 30. The 1:1 adduct of 18C6 and tetrafluoroisphthalic acid and water.

4.5

Synthesis and Results

4.5.1 Dibenzo-18-crown-6/4-nitroaniline 1:1 (A)
Synthesis: In a typical reaction, 30 mg (8.32x10-5 mol) Dibenzo-18-crown-6 and 17 mg
(1.23x10-4 mol) 4-nitroaniline were dissolved in approximately 5 mL benzene. Slow
evaporation of the solvent for approximately a week yielded yellow 1:1 dibenzo-18crown-6/4-nitroaniline crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
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Crystal packing: The co-crystals are sustained by hydrogen bonds between the amine
hydrogens and four ether linkages from the crown. The two amino hydrogens involved
in the H-bond are bifurcated. Distances range between 3.050-3.115Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3459 cm-1 (N-H stretch, 1° amine, 4nitroaniline); 1310, 1248, 1217 cm-1 (C-O stretching, crown).
Melt-temp: 120-122°C
X-ray powder diffraction: experimental done, calculated could not be done. 16.451,
19.422, 20.340, 21.284, 21.422, 21.601, 21.749, 24.416.

4.5.2

Dibenzo-18-crown-6/2-methyl-4-nitroaniline 1:1 (B)

Synthesis: In a typical reaction, 30 mg (8.32x10-5 mol) dibenzo-18-crown-6 and 14 mg
(9.20x10-5 mol) of 2-methyl-4-nitroaniline were dissolved in approximately 5 mL
benzene. Slow evaporation of the solvent for approximately a week yielded yellow 1:1
dibenzo-18-crown-6/2-methyl-4-nitroaniline crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: The co-crystals are sustained by hydrogen bonds between the amine
hydrogens and three oxygens from the crown. One of the amino hydrogens involved in
the H-bond are bifurcated, the other is involved in a H-bond with just one oxygen. The
H-bond distances range between 2.484-3.465Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3369 cm-1(N-H stretch, 1° amine, 2methyl-4-nitroaniline); 1306, 1248cm-1 (C-O stretching, crown).
Melt-temp: 137-139°C
X-ray powder diffraction: N/A
4.5.3

Dibenzo-18-crown-6/Nicotinamide 1:1 Polymorph A (C)

Synthesis: In a typical reaction, 29 mg (8.05x10-5 mol) Dibenzo-18-crown-6 and 28 mg
(1.53x10-4 mol) of nicotinamide were dissolved in approximately 4 mL THF. Slow
evaporation of the solvent for approximately a week yielded white 1:1 dibenzo-18crown-6/nicotinamide crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
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Crystal packing: The co-crystals are sustained by hydrogen bonds between one of the
amino hydrogens and two ether linkages from the crown. The amino hydrogen involved
in the H-bond is bifurcated. Distances range between 3.134-3.161Å. The other hydrogen
is at a distance of 3.330-3.362 Å away from two ether linkages as well. This co-crystal
has the nicotinamide molecule bonded through the outside of the crown ether bowl and
will be referred to as Polymorph A.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3334 cm-1(N-H stretch, 1° amine,
nicotinamide); 1326, 1252, 1227 cm-1 (C-O stretching, crown).
Melt-temp: N/A
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 13.239(13.092), 17.761(17.853), 19.679(19.482),
22.006(22.134), 22.358(22.383), 24.142(24.170), 26.479(26.360), 30.239(30.256).
4.5.4

Dibenzo-18-crown-6/nicotinamide 1:1 Polymorph B (D)

Synthesis: In a typical reaction, 290 mg (8.05x10-4 mol) Dibenzo-18-crown-6 and 123
mg (1.01x10-3 mol) of nicotinamide were dissolved in approximately 24 mL THF. Slow
evaporation of the solvent for approximately a week yielded white 1:1 dibenzo-18crown-6/nicotinamide crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: The co-crystals are sustained by hydrogen bonds between the two amino
hydrogens and two ether linkages from the crown. Distances range between 2.9953.043Å. This co-crystal has the nicotinamide molecule bonded through the inside of the
crown ether bowl and will be referred to as Polymorph B.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3349 cm-1(N-H stretch, 1° amine,
Nicotinamide); 1256, 1217 cm-1 (C-O stretching, crown).
Melt-temp: 158-160°C
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 13.038(13.081), 17.736(17.842), 20.100(20.133),
20.985(21.125), 22.225(22.201), 22.432(22.418), 23.716(23.751), 26.219(26.337),
27.753(27.929), 30.052(30.191).
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4.5.5

18-crown-6/2,6-diaminopurine 1:1 (E)

Synthesis: In a typical reaction, 31 mg (1.17x10-4 mol) 18-crown-6 and 30 mg (2x10-4
mol) 2,6-diaminopurine were dissolved in approximately 4 mL ethanol. Slow
evaporation of the solvent for approximately a week yielded white 1:1 18-crown-6/2,6diaminopurine crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: The co-crystals are sustained by hydrogen bonds between the secondary
amine hydrogen and ether linkages from the crown. Two 2,6-diaminopurine molecules
are involved in a dimer (NH2…N). The secondary amine is then H-bonded to a crown
oxygen. Distances range between 2.836-3.072Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3319 cm-1 (N-H stretch, 1° amine,
2,6-diaminopurine); 3443 and 3478 cm-1 (secondary amine); 1391 cm-1 (C-O stretching,
crown).
Melt-temp: 223-227°C
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 9.382(9.459), 12.641(12.767), 18.441(18.347), 18.899(18.982),
21.077(21.468), 22.960(22.640), 24.669(24.695), 24.801(24.877),
28.204(28.221).
4.5.6 18-crown-6/dicyandiamide 1:1 (F)
Synthesis: In a typical reaction, 30 mg (1.13x10-4 mol) 18-crown-6 and 9 mg (1.07x10-4
mol) of dicyandiamide were dissolved in a solvent system of 2mL of ethyl ether and 2mL
of methanol. Heated the solution, then slow evaporation of the solvent system for
approximately a week. Yielded colorless 1:1 dibenzo-18-crown-6/nicotinamide crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: The co-crystals are sustained by hydrogen bonds between the two amino
hydrogens from the dicyandiamide and two ether linkages from the crown. Distances
range between 2.901-2.998Å
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3341, 3147 cm-1 (N-H stretch, 2°
amine); 2878 cm-1 (2° amide); 1640 cm-1 (C=O),1096 cm-1 (C-O stretching).
Melt-temp: 198-201
X-ray Powder Diffraction: in 2θ, simulated derived from the single the single crystal
data; experimental (simulated): 9.680(9.837), 14.897(15.124), 17.239(17.181),
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19.521(19.748), 20.403(20.389), 23.359(23.325), 23.519(23.802), 23.779(23.849),
26.281(26.441), 27.567(27.519), 27.856(27.844), 29.143(29.483), 29.998(29.810).
4.5.7

18-crown-6/5-aminoisophthalic acid 1:1 (G)

Synthesis: In a typical reaction, 30 mg (1.134x10-4 mol) of 18-crown-6 and 21 mg
(1.23x10-4 mol) of 5-aminoisophthalic acid were dissolved separately in 2mL toluene and
2mL THF respectively. The two solvent mixtures were layered on top of one another
according to their densities, with a 1mL layer of blank THF separating the two layers to
make diffusion slower. The reaction vial remained tightly capped in order to avoid
solvent evaporation. A few days later 1:1 crystals emerged.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: Crystallization of 18-C-6 and 5-aminoisophthalic acid affords a 1:1
supramolecular complex sustained in a honeycomb network by carboxylic acid dimers
and between amino hydrogens and the crown ether linkages. Distances range between
2.545-2.748Å for the carboxylic acid dimer and 3.008-3.179 Å for the two amino
hydrogens and two ether linkages.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3437, 3356 cm-1 (N-H stretch, 2°
amine); 2878 cm-1 (2° amide); 1342, 1261, 1110 cm-1 (C-O stretching).
Melt-temp: 276-280°C
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 14.528(14.761), 18.144(18.407), 19.100(19.521),
20.502(20.953), 22.558(22.317), 24.021(24.425), 24.898(25.098), 25.880(25.954).

4.5.8

18-crown-6/tetrafluoroisophthalic acid 1:1 (H)

Synthesis: In a typical reaction, 30 mg (1.134x10-4 mol) of 18-crown-6 and 25 mg
(1.05x10-4 mol) tetrafluoroisphthalic acid were dissolved in approximately 1 mL of
methanol. Slow evaporation of the solvent for approximately a month yielded yellow 1:1
crystals.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix C
Crystal packing: Crystallization of 18-C-6 and tetrafluoroisophthalic acid/H2O affords a
1:1 supramolecular complex sustained by hydrogen bonds of OH groups and ether
linkages through a bridging water molecule. The HO…O distance is 2.553Å.
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Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). N/A, not enough crystal sample and
could not reproduce results.
Melt-temp: N/A
X-ray powder diffraction: N/A
4.6 Discussion
Presented above were eight examples of the use of supramolecular synthesis to
generate new compositions of matter that contains molecules of interest to materials
scientists. These results also indicate that hitherto inaccessible alignments of dipoles can
be generated and that polymorphism in multiple component phases further adds to the
structural diversity of such compounds. Although all structures presented involved
hydrogen bond donors (amines, carboxylic acids, etc), the crystal structure was not
uniform from co-crystal to co-crystal. Geometry, sterics, solvent systems, and synthons
in the additives accounted for many differences when compared to the pure crystal
structures of the pure crown ethers. It is important to point out that not all available
hydrogen atoms were involved, in the hydrogen bonding. There are distance ranges
(obtained from statistical data) that must be taken into account. These supramolecular
complexes show how ether linkages in pharmaceutical drugs can be exploited via crystal
engineering. This has increased the potential to control solid-state structures, changing
their physical properties and leading to improved solubility and bioavailability.
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Chapter 5
Trimesic Acid
5.1 Porous Materials
Trimesic acid (benzene-1,3,5-tricarboxylic acid, TMA) predictably generates
honeycomb networks with interesting supramolecular properties because of its molecular
symmetry and complementary hydrogen-bonding capabilities.26

O

OH

O

O

OH

OH

Figure 31. Trimesic acid stick models. The hydrogens have been omitted for clarity.

Hydrogen-bonded supramolecular synthons represent a primary tool for crystal
engineering.27 The rational design of host lattices using the principles of crystal
engineering9,28,29 and self-assembly through supramolecular synthons has increased in the
last few years. Of particular interest are the efforts to create new clathrates or
nanoporous materials, in which the target network is porous, contrary to Kitaigorodski’s
principle of close crystal packing.30 Open framework structures of Trimesic acid can be
designed via crystal engineering to build porous hydrogen bonded honeycomb networks.
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The directional motif formed by the acid…acid dimer (Figure 1), along with the
symmetric placement of acid groups around the benzene ring, derives the desired
honeycomb framework with 14Å pores or cavities.31 These pores encapsulate aromatic
guests.
Figure 32. Acid…Acid Dimer motif representing a hydrogen-bonded supramolecular homosynthon.

HO

O

OH

O

Table 9. Table shows the results of a CSD analysis of 1116 entries with the COOH…COOH synthons.

Average

Range

σ

2.657Å

2.554-3.196Å

0.06443

Porous materials are crystalline or amorphous solids that permit the inclusion of small
molecules through holes in their structures. Structural chemists and materials scientists
have been interested in building these frameworks not only to understand their design
principles, but also because of their diverse commercial applications such as chemical
separation, asymmetric synthesis, catalysis, storage, etc. Interpenetration of the host
lattice is undesirable for porous networks because it fills space and usually produces
global structural changes.29
Very few organic hydrogen bonded networks have been analyzed to date. A survey of
the Cambridge Structural Database14 (CSD) showed the crystal structure of tetrakis(4ethynylphenyl)methane as the first example of a diamondoid packing motif generated by
weak hydrogen bonding. A three-dimensional network is formed by hydrogen bonds
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between the alkynyl groups of four separate molecules, which meet to form the nodes of
the network. This network is absent of any guest molecules.32
Another example of an aromatic hydrogen bonded network is the orthogonal
anthracene-bis(resorcinol) tetraol, a host structure that builds an extensive hydrogenbonded network resulting in a molecular sheet. This sheet contains large supramolecular
cavities, which incorporate two molecules of solvent guest.33 The crystal packing of this
structure is comparable to the 3-connected honeycomb network coordination polymer,
topologically equivalent to the 2-D brick wall.34 This organic network is held together by
H-bonds between the OH groups of the host molecules creating cavities. Each
supramolecular cavity can bind a guest molecule (i.e. benzophenone) via hydrogen
bonded OH groups of the host and the carbonyl group of the guest.32

5.2 TMA Polymorphic Forms
Trimesic acid has been identified in four polymorphic forms, α35,β36,γ36 and δ37
(Figure 2). All of these polymorphs contain the carboxylic acid homosynthon, which
generates the expected honeycomb network with an approximate 14Å diameter void.
The α-form was developed by a solvent free host with non-planar two-dimensional
interpenetrated networks with large rings created by six molecules of Trimesic acid.11
The β-form is enantiotropically transformed from heating the α-form at high temperature
(~543K).12 Since the β-form is a polycrystalline phase, no known crystal structure exists
for the β polymorph.12 The γ-form is the flat triple catenated honeycomb network with
inclusion of small guest molecules and it is less closely packed than the α-form.12 The δ-
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form possesses large channels which do not interpenetrate, but rather include guest
molecules of bigger size.13

1)

2)

3)

Figure 33. Schematic representations of TMA forms: 1) α-form; non-planar interpenetrated honeycombs,
2)γ-form; planar triply interpenetrated honeycombs, and 3) δ-form; non-interpenetrated honeycombs.
There is no known form of the β-form at room temperature.

5.3 Strategy
Attempts to prepare the pure trimesic acid honeycomb network (with COOH dimer
distances ranging from 2.609-2.657 Å) phase by breaking the interpenetration was carried
out with different guest molecules, such as toluene, naphthalene, anthracene, acetic acid
and biphenyl. During this study, a new TMA honeycomb network truncated by acetic
acid molecules was observed. Additionally, this new form of TMA, ε-form, was
observed when toluene and naphthalene are the aromatic guests held in the TMA
honeycomb network cavities. Having studied each of these phases structurally, we then
studied the thermal stability of these crystals by Thermal Gravimetric Analysis (TGA)
experiments since the honeycomb network remained in single crystal form even after
guest removal.
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Table 10. Trimesic Acid Supramolecular Complexes

Trimesic Acid/Biphenyl
Trimesic acid/Anthracene
Trimesic acid/Acetic acid
Trimesic acid/Naphthalene
Trimesic acid/Toluene

A
B
C
D
E

BIPHENYL

ANTHRACENE

CH 3

O
H3C

OH

ACETIC ACID

NAPHTHALENE

TO LUENE

Figure 34. Structures of the co-crystal formers used in the supramolecular complexes with TMA.

5.4 Structures
5.4.1 Trimesic acid/biphenyl (A)
Laboratory results similar to the TMA δ-form include the TMA honeycomb networks
with biphenyl and anthracene as the aromatic guests occupying the cavities. Crystals of
TMA/biphenyl A were grown from CS2/AcOH/Ethanol (EtOH); crystallized in the
monoclinic P21 noncentric space group and the asymmetric unit cell consists of four
trimesic acid molecules and three biphenyl molecules. The TMA/biphenyl structure
differs from other TMA honeycomb networks because it does not include any solvent
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molecules. The honeycomb is held together by carboxylic acid dimers ranging in
distance from 2.605 to 2.627 Å, falling within the acceptable range reported in Figure 1.

Figure 35. TMA honeycomb network with biphenyl guests in the cavity.

5.4.2 Trimesic acid/anthracene (B)
Upon crystallization of TMA/anthracene B from CS2/AcOH/EtOH solvent system,
crystals were obtained in the 2:1:1 ratio of TMA/anthracene/AcOH in the monoclinic
P21/c space group. The structure is not interpenetrated and each honeycomb framework
(TMA dimer distance of 2.590-2.614 Å) encloses one anthracene molecule by creating CH…O (anthracene…TMA) interactions and an acetic acid dimer orthogonal to it (acetic
acid dimer distance of 2.643 Å). Again, the C-H…O hydrogen bond is due to guest
inclusion rather than the stabilization of the guest by the C-H…O hydrogen bonds.

Figure 36. TMA honeycomb with anthracene and acetic acid dimer guests in the cavity.
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5.4.3 Trimesic acid/acetic acid (C)
Crystals of TMA/acetic acid (AcOH) C were obtained when trimesic acid was
crystallized from CS2/AcOH/EtOH. It crystallizes in the Pī space group with six
molecules of trimesic acid and three molecules of acetic acid in the asymmetric unit. Of
the three acetic acid molecules, two produce the acetic acid dimer (Dimer distance of
2.647Å) and the third one is used in constructing the truncated TMA honeycomb network
(dimer distance of 2.717 Å). Analysis of the packing of TMA/AcOH reveals that they
are closely related to the γ-form, but differ by the incorporation of the acetic acid in the
network. The acetic acid forms the truncated honeycomb by terminating the normal twodimensional honeycomb framework. It is unclear why the dimer between the acetic acid
(strong acid) – trimesic acid (weak acid) COOH…COOH synthon is formed. It may be
rationalized that in order to include the guest, the void space must be created by
terminating the two-dimensional honeycomb framework with acetic acids.

Figure 37. Truncated acetic acid TMA honeycomb network.
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Results showing the new TMA polymorph with acetic acid truncated honeycomb
networks, ε-form, were obtained with naphthalene and toluene as the guest molecules
(Figure 6 and 7).

5.4.4 Trimesic acid/Naphthalene (D)
Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of
TMA/naphthalene/acetic acid. Due to the smaller size of the guest, the framework is
triply interpenetrated (as in TMA polymorphic forms α and γ) but differs from these
forms because the acetic acid instead of creating dimers with itself, generates the
acid…acid (distance of 2.624-2.704 Å) dimer with trimesic acid, truncating the TMA
honeycomb network. Trimesic acid forms an infinite two-dimensional honeycomb
network (TMA dimer distance of 2.582-2.623 Å), which interpenetrates with three
truncated honeycomb networks. The naphthalene guest molecules are disordered,
occupying the void created between the interpenetration rather than fitting into the
honeycomb framework.

Figure 38. TMA honeycomb networks with acetic acid truncated networks with naphthalene.
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5.4.5

Trimesic acid/Toluene (E)

Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of TMA/toluene/acetic
acid. Due to the smaller size of toluene, the framework is triply interpenetrated (as in
TMA polymorphic forms α and γ) but differs from these forms because the acetic acid
instead of creating dimers with itself, generates the acid…acid (as in D) (TMA dimer
distance of 2.605-2.632 Å, TMA-Acetic acid dimer distance of 2.6209-2.710 Å).

Figure 39. TMA honeycomb networks with acetic acid truncated networks with toluene guests.

5.5 Synthesis and Results
5.5.1 Trimesic Acid/biphenyl (A)
Synthesis: In a typical reaction, 58 mg (2.76x10-4 mol) of TMA and 47 mg (3.05x10-4
mol) of biphenyl were layered in 6 mL ethanol and 6 mL CS2, respectively. A 4 mL
layer of acetic acid separated the two layers. Slow evaporation and in approximately two
weeks crystals appeared.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix D

53

Crystal Packing: TMA honeycomb networks with biphenyl as the aromatic guests
occupying the cavities. The honeycomb is held together by carboxylic acid dimers
ranging in distance from 2.605 to 2.627Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Not much changes from pure TMA
since the honeycomb network remained the same. The peaks did shift slightly downfield.
3127 cm-1 (-OH stretch), 1691 cm-1 (C=O stretch), 1261 cm-1 (C-O stretch).
Melt-temp: 362-370ºC
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 9.296(9.297), 12.240(12.112), 16.081(16.374), 17.243(17.480),
22.206(22.330), 26.721(26.769), 33.499(33.370).

5.5.2 Trimesic Acid/anthracene (B)
Synthesis: In a typical reaction, 20 mg (9.51x10-4 mol) of TMA and 17 mg (9.54x10-5
mol) of anthracene were layered in 1 mL ethanol and 1 mL CS2, respectively. A 1 mL
layer of acetic acid separated the two layers. Slow evaporation and in approximately two
to three weeks crystals appeared.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix D
Crystal packing: Crystallization of TMA with anthracene resulted in a structure that is
not interpenetrated and each honeycomb framework (TMA dimer distance of 2.590-2.614
Å) encloses one anthracene molecule by creating C-H…O (anthracene…TMA)
interactions and an acetic acid dimer orthogonal to it (acetic acid dimer distance of 2.643
Å).
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Not much changes from pure TMA
since the honeycomb network remained the same. The peaks did shift slightly downfield.
3209 cm-1 (-OH stretch), 1698 cm-1 (C=O stretch), 1276 cm-1 (C-O stretch).
Melt-temp: started melting 278ºC, decomposed before melting completely.
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 11.035(11.056), 12.526(12.480), 13.010(13.070),
14.198(14.121), 17.324(17.153), 22.979(22.905), 23.080(23.035), 25.119(25.111),
26.300(26.314), 27.121(27.188), 30.011(30.002).
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5.5.3

Trimesic Acid/acetic Acid (C)

Synthesis: In a typical reaction, 24 mg (1.14x10-4 mol) of TMA was dissolved in 1 mL
of ethanol. Separately, 4 drops of benzene were dissolved in 1 mL of CS2. The two
layers were put in a reaction vial with a 1 mL layer of acetic acid between then to slow
down diffusion. Slow evaporation and in approximately two weeks crystals appeared.
The benzene served only as a template and did not appear in the crystal structure.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix D
Crystal Packing: Crystallization of TMA and acetic acid results in a 1:1 supramolecular
complex that is sustained by carboxylic acid H-bonds. The acetic acid forms the
truncated honeycomb by terminating the normal two-dimensional honeycomb
framework. Distances range between 2.647-2.717 Å.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Not much changes from pure TMA
since the honeycomb network remained the same. The peaks did shift slightly downfield.
3117 cm-1 (-OH stretch), 1684 cm-1 (C=O stretch), 1397 and 1275 cm-1 (C-O stretch).
Melt-temp: 363-364ºC
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 12.887(12.906), 19.962(19.669), 20.037(20.039),
22.463(22.461), 24.442(368), 26.841(26.974), 29.183(29.173), 30.319(30.333),
30.880(30.879), 33.475(33.478), 35.127(35.127), 36.158 (36.154), 37.638(37.674),
39.562(39.561).

5.5.4

Trimesic Acid/naphthalene (D)

Synthesis: In a typical reaction, 21 mg (9.99x10-5 mol) of TMA and 11 mg (8.58x10-5
mol) of naphthalene were dissolved separately in 1 mL ethanol and 1 mL CS2,
respectively. A 1 mL layer of acetic acid separated the two layers. Slow evaporation and
in approximately two weeks crystals appeared.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix D
Crystal Packing: Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of
TMA/naphthalene/acetic acid. Due to the smaller size of the guest, the framework is
triply interpenetrated (as in TMA polymorphic forms α and γ), but differs from these
forms because acetic acid instead of creating dimers with itself, generates the acid…acid
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dimer (distance of 2.624-2.704Å) with TMA, truncating the TMA honeycomb network.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Not much changes from pure TMA
since the honeycomb network remained the same. The peaks did shift slightly downfield.
3138 cm-1 (-OH stretch), 1684 cm-1 (C=O stretch), 1268 cm-1 (C-O stretch).
Melt-temp: 360-363ºC
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 11.858(11.473), 12.701(12.742), 16.457(16.469),
22.960(22.900), 24.459(24.550), 26.658(26.656), 27.824(27.806), 30.897(30.877),
35.265(35.260).

5.5.5

Trimesic Acid/toluene (E)

Synthesis: In a typical reaction, 25 mg (1.19x10-4 mol) of TMA was dissolved separately
in 1 mL ethanol and ~5 drops of toluene was dissolved in 1 mL CS2, respectively. A 1
mL layer of acetic acid separated the two layers. Slow evaporation and in approximately
two days crystals appeared.
Crystal data: (Bruker SMART-APEX CCD Diffractometer). Appendix D
Crystal Packing: Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of
TMA/toluene/acetic acid. Due to the smaller size of the guest, the framework is triply
interpenetrated, but differs from these forms because acetic acid instead of creating
dimers with itself, generates the acid…acid dimer (distance of 2.6209-2.710Å) with TMA,
truncating the TMA honeycomb network.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Not much changes from pure TMA
since the honeycomb network remained the same. The peaks did shift slightly downfield.
3127 cm-1 (-OH stretch), 1695 cm-1 (C=O stretch), 1397 and 1265 cm-1 (C-O stretch).
Melt-temp: 366-367ºC
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data;
experimental (simulated): 16.344(16.345), 20.080(20.205), 22.335(22.283),
24.522(24.567), 25.487(25.508), 27.001(27.017), 28.061(28.055), 29.301(29.351),
30.582(30.503), 30.841(30.822), 33.028(33.036), 36.099(36.096), 37.703(37.700),
39.079(39.062).
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5.6 Discussion
Is it really possible to maintain the crystallinity and pores present in the TMA
honeycomb networks even in the absence of guests? Thermal Gravimetric Analysis
(TGA) experiments carried out with the ε-form crystal of TMA/toluene and the single
crystal were performed. TGA measures the weight change in materials as a function of
time and temperature. The measurement provides basic information about the thermal
stability of a chemical and its composition (change in mass of a sample vs.
temperature).38,39 The samples were heated to 180°C to ensure the removal of all guest
molecules (a weight % loss of ~12% was evident in both TGA spectra). Single crystal Xray data revealed that cell parameters before TGA and after guest removal by TGA
remained the same, confirming retention of crystallinity and the hydrogen-bonded
network.
Table 11. TMA/toluene crystal data before and after TGA analysis.

a (Å)
b (Å)
c (Å)
α(°)
β(°)
γ (°)
Volume (Å3)
Space grp

Before
TGA
15.4991
16.2684
16.4957
119.309
90.907
117.171
N/A
P-1

After
TGA
15.2245
16.345
16.54
119.556
90.477
116.276
3072.9
P-1
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The large open honeycomb network of TMA is built by strong, yet, flexible
supramolecular synthons (acid…acid) and by accommodating aromatic guests in the
cavities. These guest molecules inhibit the honeycomb networks from interpenetrating
and assembling into a close packed conformation. Removal of the guest can be
accomplished while retaining the hydrogen bonded aromatic framework.

58

Chapter 6
Conclusion
The concept of crystal engineering was first coined by Schmidt in the context of
covalent synthesis in the solid state, i.e. topochemical reactions.2 However, recent
development of this subject has expanded it into areas as diverse as supramolecular
synthesis,3,4,9,40 crystal structure analysis and prediction41-45 and functional materials.46-48
As previously stated, the concept of crystal engineering was originally introduced in the
context of stereochemical control of photochemical reactions,2 but it has subsequently
been shown to have wider implications for materials science. In the context of
pharmaceuticals, there are important process and intellectual property implications
related to control and reproducibility of composition and polymorphism.12,49 This work
focused upon how previously known supramolecular synthons could be exploited to
rationally generate binary crystals with “engineered” compositions. The study chose
pharmaceutical molecules as the target system since they contain a wide range of
synthons and understanding of the crystal structure – physical property relationship is
essential for the continued application of these essential chemicals toward improving the
overall health of society.
Hydrogen bonded supramolecular synthons represent a prototypal tool for crystal
engineering9 and can be categorized as follows: 1) self-complementary synthons, in
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which a single molecule self-assembles to form a “homosupramolecular synthon” (e.g.
carboxylic acid dimer) or 2) two or more complementary components, thereby creating a
multiple component or “heterosupramolecular synthon” (e.g. the hetero-dimer formed by
pyridines and carboxylic acids).
Supramolecular synthetic approaches offer a number of attractive features: the ability
to exploit readily available molecules or ions in novel ways; their inherent modularity
affords compositional and structural diversity; the use of non-covalent interactions makes
for facile synthesis. In short, supramolecular synthesis offers a combinatorial type of
approach to synthesis of new structures and can afford a wide range of structural diversity
without the need to break and form covalent bonds. The phenomenon of polymorphism
in crystal engineering cannot be ignored. Polymorphism is defined as the phenomenon
where the same chemical substance exists in different crystalline forms or different
crystalline patterns.11 This phenomenon is more common among molecules with flexible
conformations capable of hydrogen bonding.6 Supramolecular synthons are the
structural units within molecules, which can be formed and/or assembled by synthetic
operations6. The supramolecular synthons present in polymorphic forms may be intact
from form to form, therefore it can be stated that the supramolecular equivalents of
structural isomers are crystalline polymorphs.6 The criteria for assessing the existence of
polymorphs are different unit cell parameters, crystal packing arrangements and physical
properties.11
Rationally generating organic binary crystals that contain pharmaceutical components
by exploiting supramolecular chemistry concepts should further the development of other
novel pharmaceutical phases. Indeed, the creation of model binary crystals provides
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supramolecular insight that could lead to structures that have a pharmaceutical
advantage50 over the pure phase pharmaceuticals. The necessary information to create
and develop binary crystals should be stored already in the known pharmaceutical
molecule. It should be intuitive that modular structures, e.g. binary crystals based upon
more than one component, are often more diverse and controllable than single component
phases. It is now evident that supramolecular chemistry, defined as chemistry beyond the
molecule,4 and “supramolecular assemblies” are inherently linked to the concepts of
crystal engineering.
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Appendix A: Crystallographic Data for Nifedipine Structures

A
Formula

B

C

C18H21N3O7 C92H96N12O28 C27H26N4O6

m.p. (°C)

136-138

148-153

137-139

Mol. Wt.

391.38

1817.81

502.52

Triclinic

Monoclinic

Triclinic

P-1

P2(1)n

P-1

a (Å)

7.8268(11)

7.9310(14)

7.6332(7)

b (Å)

10.667(15)

12.4945(22) 9.8375(9)

c (Å)

11.8401(16) 22.2611(37) 16.6567(15)

Crystal System
Space Group

α (°)

70.065(3)

90

101.689(2)

β (°)

76.766(3)

90.198(8)

93.132(2)

γ (°)

80.56(3)

90

95.396(2)

Volume (Å3)

900.7(2)

calc density (mg/cm3)
Solvent

2205.93(4) 1215.92(19)

1.443

1.373

1.373

Formamide

Methanol

Methanol
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Appendix B: Crystallographic data for Phenytoin Structures
A

B

C

Formula

C80H22N4O2

C80H64N12O8

C27H22N4O2

m.p. (°C)

234-239

225-227

254-257

Mol. Wt.

347.37

440.48

434.49

Monoclinic

Monoclinic

Triclinic

P21/c

P21/c

P-1

a (Å)

16.6583(19)

8.0106(10)

8.620(14)

b (Å)

8.8478(10)

26.2398(33)

9.929(14)

c (Å)

11.9546(14)

7.981(10)

13.29(2)

α (°)

90

90

87.47(4)

β (°)

96.618(2)

91.069(2)

84.03(3)

γ (°)

90

90

86.13(3)

1750.2(3)

1677.4(4)

1128(3)

1.318

1.308

1.28

Crystal System
Space Group

Volume (Å3)
calc density (mg/cm3)
Solvent

Ethanol/acetone 2,4-pentanedione 2,4-pentanedione
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Appendix C: Crystallographic Data for Crown Ether Structures

A

B

C58H66N6O18

C27H30N2O7

m.p. (°C)

120-122

137-139

N/A

158-160

284-286

194-198

276-280

1997.84

Mol. Wt.

1135.17

512.55

482.52

482.52

1240.206

432.5

1129.14

1997.84

Orthorhombic

Monoclinic

Fdd2

P21/n

Formula

Crystal System
Space Group

C

D

E

F

G

H

C26H30N2O7 C26H30N2O7 C51H87N18O18 C16H32N8O6 C60H60N2O20 C78H132O39F16

Monoclinic Orthorhombic Monoclinic

P21/c

P212121

P21/c

Monoclinic Orthorhombic Monoclinic

I2/a

C2

P21/n

a (Å)

42.769(3)

13.5993(14) 15.956(3) 8.4015(13) 7.9634(28) 15.452(2) 7.6625(48) 8.8849(28)

b (Å)

52.193(3)

9.3950(10) 9.8132(16) 13.650(2) 13.8565(51) 8.1949(10) 16.929(99) 20.584(71)

c (Å)

11.1128(7)

20.885(2)

β (º)

90

Volume (Å3)
calc density
mg/cm3)
Solvent

17.266(3) 20.705(3) 12.6933(40) 18.215(3) 11.713(73) 14.102(42)

103.445(2) 111.615(3)

90

2513.3(7) 2374.5(7)

94.661(12) 99.445(2)

24806(3)

2595.2(5)

1.216

1.312

1.275

1.35

1.475

Benzene

Benzene

THF

THF

Ethanol

68

1396.008

90

105.952(8)

2275.2(6) 1579.4(16) 2479.67(4)
1.263
Ether/
Methanol

1.317

1.338

Toluene/
THF

Methanol

Appendix D: Crystallographic Data for Trimesic Acid Structures.

A

B

C

D

E

Formula

C72H54O24

C34H24O24

C120H96O84

C133H98O42

C126H112O48

m.p. (°C)

362-370

decomposed

363-364

360-363

366-367

Mol. Wt.

186.16

656.53

2881.97

2368.11

2418.18

Monoclinic

Monoclinic

Triclinic

Triclinic

Triclinic

P21

P-1

P-1

P-1

P-1

a (Å)

9.9791(10)

10.4027(8)

15.4543(14)

15.4148(21)

15.4991(34)

b (Å)

28.424(3)

16.3494(15)

16.3203(22)

16.2684(35)

c (Å)

11.0164(11)

10.4430(8)

16.5130(14)

16.3669(23)

16.4957(36)

α (°)

90

90

119.409(2)

119.516(2)

119.309(6)

β (°)

104.243(3)

105.226(2)

90.449(2)

90.349(3)

90.907(9)

γ (°)

90

90

117.481(1)

117.499(2)

119.171(5)

3028.7(5)

2993.7(4)

3072.21(2)

3029.29(7)

3069.21(5)

1.429

1.312

1.558

1.298

1.308

Crystal System
Space Group

Volume (Å3)
calc density (mg/cm3)
Solvent

28.560(2)

CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH
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